

Registration deadline 12 May 2021

Provisional Draft Agenda
57th meeting of the Committee for Risk Assessment

31 May-3 June
and
8-10 June 2021

Virtual meeting

31 May starts at 14.00
10 June ends at 17:30

Times are Helsinki times

Item 1 – Welcome and Apologies

Item 2 – Adoption of the Agenda

RAC/A/57/2021
For adoption

Item 3 – Declarations of conflicts of interest to the Agenda

Item 4 – Appointment of (co-)rapporteurs

- 1) Appointment of (co-)rapporteurs for CLH dossiers, restriction dossiers, authorisation applications, evaluation of occupational exposure limits

For agreement
Closed session

Item 5 – Report from other ECHA bodies and activities

- 1) RAC Work Plan for all processes

For information

- 2) CLH: Procedure for agreement seeking (fast-track)

For agreement
Doc to be distributed

- 3) RAC co-opted members

For agreement
Doc to be distributed
Closed session

Item 6 – Requests under Article 77(3)(c)

- 1) Classification for environmental toxicity of lead

For discussion and adoption

Item 7 – Health based exposure limits at the workplace

Adoption of opinions

- 1) Asbestos – final draft opinion

For discussion and adoption

Item 8 – Harmonised classification and labelling (CLH)

8.1 CLH dossiers

1. Hazard classes for agreement without plenary debate (fast-track)

(To be updated later)

- Reaction mass of 1-(2,3-epoxypropoxy)-2,2-bis ((2,3-epoxypropoxy)methyl) butane and 1-(2,3-epoxypropoxy)-2-((2,3-epoxypropoxy)methyl)-2-hydroxymethyl butane (EC: -; CAS: -) – germ cell mutagenicity, reproductive toxicity (*discussed in the CLH WG*)
- Sodium chlorate (EC: 231-887-4; CAS: 7775-09-9) – acute oral toxicity, hazardous to the aquatic environment (*discussed in the CLH WG*)
- Potassium chlorate (EC: 223-289-7; CAS: 3811-04-9) – acute oral and inhalation toxicity, hazardous to the aquatic environment (*discussed in the CLH WG*)
- Triethylamine (EC: 204-469-4; CAS: 121-44-8) – acute inhalation and dermal toxicity, serious eye damage/eye irritation (*discussed in the CLH WG*)
- Di-n-butylamine (EC: 203-921-8; CAS: 111-92-2) – acute oral, dermal and inhalation toxicity, skin corrosion/irritation, serious eye damage/eye irritation, STOT SE (*discussed in the CLH WG*)

2. Hazard classes for agreement with plenary debate

- 1) Reaction mass of 1-(2,3-epoxypropoxy)-2,2-bis ((2,3-epoxypropoxy)methyl) butane and 1-(2,3-epoxypropoxy)-2-((2,3-epoxypropoxy)methyl)-2-hydroxymethyl butane (EC: -; CAS: -) – *developmental toxicity*
- 2) Triethylamine (EC: 204-469-4; CAS: 121-44-8) – *acute oral toxicity*
- 3) Difenoconazole (ISO); 1-({2-[2-chloro-4-(4-chlorophenoxy)phenyl]-4-methyl-1,3-dioxolan-2-yl}methyl)-1H-1,2,4-triazole; 3-chloro-4-[(2RS,4RS;2RS,4SR)-4-methyl-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-2-yl]phenyl 4-chlorophenyl ether (EC 601-613-1; CAS 119446-68-3)
- 4) 4-Nitrosomorpholine (EC: 627-564-6; CAS: 59-89-2)
- 5) N,N-dimethyl-p-toluidine (EC: 202-805-4; CAS: 99-97-8)
- 6) Metribuzin (ISO); 4-amino-6-tert-butyl-3-methylthio-1,2,4-triazin-5(4H)-one; 4-amino-4,5-dihydro-6-(1,1-dimethylethyl)-3-methylthio-1,2,4-triazin-5-one (EC: 244-209-7; CAS: 21087-64-9)
- 7) [1] Lithium carbonate; [2] lithium chloride; [3] lithium hydroxide (EC: [1] 209-062-5; [2] 231-212-3; [3] 215-183-4; CAS: [1] 554-13-2; [2] 7447-41-8; [3] 1310-65-)
- 8) Nonylphenol, branched and linear, ethoxylated (with average molecular weight < 352 g/mol) [includes ortho-, meta-, para- isomers or any combination thereof] (EC: 500-315-8; 500-024-6; 500-045-0; 500-209-1; 248-762-5; 243-816-4; 248-291-5; and others; CAS: 127087-87-0; 9016-45-9; 26027-38-3; 68412-54-4; 27986-36-3; 20427-84-3; 27176-93-8; 1119449-38-5 and others)
- 9) Nonylphenol, branched and linear, ethoxylated (with 352 g/mol ≤ average molecular weight < 704 g/mol) [includes ortho-, meta-, para- isomers or any combination thereof] (EC: 230-770-5; 248-743-1; 247-555-7; 248-293-6 and others; CAS: 127087-87-0; 9016-45-9; 7311-27-5; 27942-27-4; 26264-02-8; 27177-05-5; 14409-72-4 and others)
- 10) Nonylphenol, branched and linear, ethoxylated (with 704 g/mol ≤ average molecular weight ≤ 1540 g/mol) [includes ortho-, meta-, para- isomers or any combination thereof] (EC: -; CAS: 127087-87-0; 9016-45-9 and others)

For discussion and adoption

Item 9 – Restrictions

9.1 General restriction issues

1. Framework for RAC and SEAC in checking conformity and developing opinions on restriction proposals
2. Update on the Restrictions Task Force meeting (29/4)

9.2 Restriction Annex XV dossiers

1) Conformity check and key issues discussion

- 1) 1,6,7,8,9,14,15,16,17,17,18,18-Dodecachloropentacyclo-[12.2.1.1^{6,9}.0^{2,13}.0^{5,10}]octadeca-7,15-diene ("Dechlorane Plus"TM)

For discussion and agreement

2) Opinion development

- 1) Undecafluorohexanoic acid (PFHxA), its salts and related substances – fourth draft opinion

For discussion and agreement

- 2) Substances in single-use baby diapers – second draft opinion

For discussion and agreement

- 3) Lead and its compounds in ammunition and fishing tackles – first draft opinion

For discussion

Item 10 – Authorisation

10.1 General authorisation issues

- 1) Update on incoming/future applications
- 2) Report from RAC WG on AfAs during May 2021 meeting
- 3) Update of the opinion format
- 4) Evaluation of review reports

For information/discussion

10.2 Authorisation applications

1. Discussion on key issues
 - 1) 5 applications for authorisation (chromium trioxide, chromic acid, dichromium tris(chromate)) from February 2021 submission window

For discussion

10.3 Agreement on draft opinions

1. Draft opinions for agreement without plenary debate (A-list)

- 1) To be added

2. Draft opinions for agreement with plenary debate

1. 218_CT_DOURECA (2 uses)
2. 219_CT_HusqvarnaAB (1 use)
3. 220_CT_SRG Global (2 uses)
4. 221_CT_SD_USSK (1 use)
5. 222_RR1_SD_Colle (1 use)

6. 223_RR1_EDC_Lanxess (1 use)
7. 224_RR1_EDC_Eurenco (1 use)
8. 225_MOCA_Luc (2 uses)
9. 226_OPE_LETI (1 use)

For discussion and agreement

10.4 Adoption on opinions

1. 196_OPE_Becton (1 use)
2. 198_OPE_Zoetis (4 uses; comments on Use 4 only)
3. 199_OPE_Biokit (2 uses; comments on Use 2 only)
4. 203_OPE_NPE_Qiagen (4 uses)

For discussion and adoption

Item 11 – AOB

1. Update form the ECHA legal services on the current legal cases

For information

Item 12 – Minutes of RAC-57

- 1) Table with Summary Record of the Proceedings, and Conclusions and Action points from RAC-57

For adoption

PROVISIONAL TIMELINE FOR THE DISCUSSIONS AT RAC-57 – WEEK 1

Please note that this timeline is provisional. Changes can be made before and during the meeting in order to accommodate the discussions.

Monday 31 May 2021: Afternoon session

- Item 1 – Welcome and Apologies
- Item 2 – Adoption of the Agenda
- Item 3 – Declarations of conflicts of interest to the Agenda
- Item 5 – RAC Work Plan for Restriction, Authorisation and C&L processes
- Item 11 – AOB
- Item 7 – OEL

Tuesday 1 June 2021: Morning session

- Item 9 – Restrictions

Tuesday 1 June 2021: Afternoon session

- Item 7 – OEL
- Item 9 – Restrictions

Wednesday 2 June 2021: Morning session

- Item 9 – Restrictions

Wednesday 2 June 2021: Afternoon session

- Item 9 – Restrictions
- Item 10 – Authorisation applications

Thursday 3 June 2021: Morning session

- Item 10 – Authorisation applications

Thursday 3 June 2021: Afternoon session

- Item 10 – Authorisation applications
- Item 12 – RAC-57A Summary Record adoption

PROVISIONAL TIMELINE FOR THE DISCUSSIONS AT RAC-57 – WEEK 2

Please note that this timeline is provisional. Changes can be made before and during the meeting in order to accommodate the discussions.

Tuesday 8 June 2021: Morning session

- Item 1 – Welcome and Apologies
- Item 3 – Declarations of conflicts of interest to the Agenda
- Item 8 – CLH dossiers

Tuesday 8 June 2021: Afternoon session

- Item 8 – CLH dossiers

Wednesday 9 June 2021: Morning session

- Item 8 – CLH dossiers

Wednesday 9 June 2021: Afternoon session

- Item 8 – CLH dossiers

Thursday 10 June 2021: Morning session

- Item 8 – CLH dossiers

Thursday 10 June 2021: Afternoon session

- Item 8 – CLH dossiers
- Item 11 – AOB
- Item 4 – Appointment of rapporteurs

Social event (optional)
